Factors influencing the use of leadless or transvenous pacemakers: results of the European Heart Rhythm Association Prospective Survey.


Journal

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
ISSN: 1532-2092
Titre abrégé: Europace
Pays: England
ID NLM: 100883649

Informations de publication

Date de publication:
01 04 2020
Historique:
received: 04 12 2019
accepted: 09 01 2020
pubmed: 22 1 2020
medline: 29 6 2021
entrez: 22 1 2020
Statut: ppublish

Résumé

To study the proportion of leadless pacemaker (LL-PM) implants and the factors influencing the choice of LL-PM vs. transvenous pacemaker (TV-PM) across tertiary centres in Europe with routine availability of the LL-PM. A European Heart Rhythm Association (EHRA) prospective snapshot survey using electronically distributed questionnaire sent to participating centres. Participating tertiary cardiac pacing centres prospectively included consecutive patients implanted between November 2018 and January 2019. Questions covered standards of care and policies used for patient management, focusing particularly on the reasons for choosing LL-PM vs. TV-PM. Overall, 21 centres from four countries (France, Netherlands, Spain, and Italy) participated, with eventual data from 798 patients (n = 472, 59% male). With 69 implants, LL-PM represented only 9% of all implants and 36% of the single-chamber pacing group; double-chamber transvenous pacemakers were implanted in 528 patients and biventricular (cardiac resynchronization pacemaker) in 79. The two major reasons reported in favour of LL-PM implantation were an anticipated high risk of infection or low rate of ventricular pacing. Compared to TV-PM, LL-PM patients were more often male (74% vs. 54%, P = 0.009), with greater proportion of valvular heart disease (45% vs. 35%, P = 0.01) and atrial fibrillation (AF; 65% vs. 23%, P < 0.0001), with significantly more comorbidities (≥ one comorbidity, 66% vs. 52%, P = 0.02). This contemporary multicentre European survey shows that LL-PM constitutes a small proportion of all PM implants. Patients implanted with LL-PM were more likely to have AF and a high anticipated risk of infection.

Identifiants

pubmed: 31960027
pii: 5710692
doi: 10.1093/europace/euz357
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

667-673

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Auteurs

Serge Boveda (S)

Cardiology, Cardiac Arrhythmias Management Department, Clinique Pasteur, 45, Avenue de Lombez, 31076 Toulouse, France.
Postgraduate Program in Cardiac EP and Pacing, Universiteit Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
INSERM U970, Paris Descartes University, Paris, France.

Eloi Marijon (E)

INSERM U970, Paris Descartes University, Paris, France.
Cardiology Department, European Georges Pompidou Hospital, Paris Cardiovascular Research Center, Paris, France.

Radoslaw Lenarczyk (R)

First Department of Cardiology and Angiology, Silesian Centre for Heart Disease, Curie-Sklodowskiej Str 9, 41-800 Zabrze, Poland.

Konstantinos E Iliodromitis (KE)

Electrophysiology Section, Department of Cardiology, Cardiovascular Center, OLV, Aalst, Belgium.

Francisco Marin (F)

Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
IMIB-Arrixaca, CIBERCV, University of Murcia, Murcia, Spain.

Pascal Defaye (P)

University Hospital of Grenoble-Alpes, 38043 Grenoble, France.

Aude Solnon (A)

Cardiology Department - CHU Laennec, Nantes, France.

Nikolaos Dagres (N)

Department of Electrophysiology, Heart Center Leipzig, Leipzig, Germany.

Tatjana S Potpara (TS)

School of Medicine, University of Belgrade, Belgrade, Serbia.
Cardiology Clinic, Clinical Center of Serbia Visegradska 26, 11000 Belgrade, Serbia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH